45
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Recently, a benefit from administration of a 3-day course of early remdesivir (ER) in the outpatients' setting was reported. However, real-life data on its use is scarce. Therefore, we explored the ER clinical outcome in our outpatients' s cohort, compared to untreated controls. We included all patients who were prescribed ER from February to May 2022 and followed them up for 3 months and compared patients who received treatment with untreated controls. In the two groups the following outcomes were investigated: hospitalization and mortality rate, time of negativization and symptom's resolution, and postacute coronavirus disease 19 (COVID-19) syndrome prevalence. Overall, 681 patients were analyzed, mostly females (53.6%), and with a median age of 66 years (interquartile range: 54-77), 316 (46.4%) patients received ER, and 365 (53.6%) did not receive antiviral treatment (control group). Overall, 8.5% patients eventually required oxygen support, 8.7% were hospitalized for COVID-19, and 1.5% died. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunization and ER (adjusted odds ratio [aOR]: 0.049 [0.015; 0.16], p < 0.001) independently reduced hospitalization risk. ER was significantly associated with a shorter duration of SARS-CoV-2 positivity at nasopharyngeal swabs (aβ -8.15 [-9.21; -7.09], p < 0.001) and of symptoms (aβ -5.11 [-5.82; -4.39], p < 0.001), and with lower rate of COVID-19 sequelae compared to control group (aOR: 0.18 [0.10; 0.31], p < 0.001). Even in the SARS-CoV-2 vaccination and Omicron era, in patients at high risk of developing severe disease, ER demonstrated to have a good safety profile and to significantly reduce the risk of disease progression and COVID-19 sequelae compared to untreated controls.

          Related collections

          Author and article information

          Journal
          J Med Virol
          Journal of medical virology
          Wiley
          1096-9071
          0146-6615
          Mar 2023
          : 95
          : 3
          Affiliations
          [1 ] Department of Molecular Medicine, Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy.
          [2 ] Infectious Disease Unit, Department of Medical Sciences at Amedeo di Savoia Hospital, University of Torino, Torino, Italy.
          [3 ] Department of Hospital Pharmacy, Padua University Hospital, Padua, Italy.
          [4 ] Department of Molecular Medicine, University of Padua, Padua, Italy.
          Article
          10.1002/jmv.28660
          36905216
          4bdec746-c474-453a-943b-511071766671
          History

          COVID-19,remdesivir,efficacy,early treatment,3-day
          COVID-19, remdesivir, efficacy, early treatment, 3-day

          Comments

          Comment on this article